NSAIDS (non-steroidal anti-inflammatory drugs) indicated for the treatment of different types of arthritis.
The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
EULAR developed provisional recommendations for the management of rheumatic and musculoskeletal diseases during the COVID-19 pandemic.
Researchers investigated the association between rheumatologist visits within 6 weeks of symptom onset and improved long-term disease outcomes in rheumatoid arthritis.
Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.
Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.